Ann: September 2022 Quarterly Report and Appendix 4C, page-19

would not follow Wilson advice at all. Brokers are too bias depending on stocks they float or raise for. Starting to think I will not follow any broker advice anymore. The stocks are in same space but one is biologic and one synthetic. Gives treating doctors point of difference. Both I feel will prosper. I have been in PNV for over 10 years. I wish you all well. But to say one is obviously much better either clinically or as a company is just wrong. Both will do well long term. PNV will continue to grow as it covers an aspect of the market burns surgeons are asking for and increasingly using; synthetics.
bill